Drug Patents owned by Kyowa Kirin
1. Drug name - NOURIANZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(2 years from now) | |
| CN1784405A | KYOWA KIRIN | Microcrystalline |
May, 2024
(1 year, 7 months from now) | |
| CN100395245C | KYOWA KIRIN | Microcrystalline |
May, 2024
(1 year, 7 months from now) | |
| EP1626049A1 | KYOWA KIRIN | Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione |
May, 2024
(1 year, 7 months from now) | |
| EP1626049B1 | KYOWA KIRIN | Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione |
May, 2024
(1 year, 7 months from now) | |
| EP1626049A4 | KYOWA KIRIN | Microcrystal |
May, 2024
(1 year, 7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(3 months from now) | |
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2023
(4 months from now) | |
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(4 years from now) | |
Drugs and Companies using ISTRADEFYLLINE ingredient
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
2. Drug name - SANCUSO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608282 | KYOWA KIRIN | Transdermal granisetron |
Jan, 2025
(2 years from now) | |
Drugs and Companies using GRANISETRON ingredient
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
| Strength | Dosage | Availability |
|---|---|---|
| 3.1MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.